Scholarlink

Objective <p>To investigate the long-term impact of half-fluence photodynamic therapy (PDT) on chorioretinal architecture in chronic central serous chorioretinopathy (cCSCR) through novel choroidal vascularity index (CVI) versus previously established subfoveal choroidal thickness (SFCT).</p> Methods <p>This post-hoc analysis included prospectively collected swept-source optical coherence tomography (SS-OCT) images of a total of 29 cCSCR and fellow eyes (FE), acquired before, one and 12 months after PDT. CVI, total choroidal area (TCA), luminal area (LA) and stromal area (SA) were calculated using validated binarization technique. Central macular thickness (CMT), SFCT and subretinal fluid (SRF) were assessed. Longitudinal changes following PDT and associations between all parameters were investigated.</p> Results <p>CVI, TCA, LA, SFCT and CMT significantly decreased at month 1 (all <i>p</i> &lt; 0.001). From month 1 to 12, CVI (<i>p</i> &lt; 0.001) and LA (<i>p</i> = 0.01) increased but remained significantly lower than at baseline (<i>p</i> = 0.001 and <i>p</i> &lt; 0.001). SFCT and CMT remained stable (all <i>p</i> = 1.0). SA and all FE parameters showed no significant changes at any time point. Comparing affected and FE, there were significant CVI differences at baseline (<i>p</i> &lt; 0.001), month 1 (<i>p</i> = 0.01) and 12 (<i>p</i> &lt; 0.001). SRF was significantly associated with higher CVI (<i>p</i> &lt; 0.001), LA (<i>p</i> = 0.031), SFCT (<i>p</i> = 0.038).</p> Conclusion <p>Half-fluence PDT significantly affects choroidal architecture, with sustained CVI and SFCT reductions 12 months post-treatment. Use of CVI as both a treatment response and disease activity marker is merited. There is a large discrepancy between CVI and SFCT, suggesting they each represent different anatomic responses. CVI proves to be a more specific and reliable CSCR biomarker than previously established SFCT.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Long-term effect of photodynamic therapy on choroidal vascularity index versus choroidal thickness as biomarkers for chronic central serous chorioretinopathy

  • 期刊论文

  • 发表日期：

    2025年1月6日

查看全文
  • Patricia T. A. Bui,
  • Martin Stattin,
  • Daniel Ahmed-Balestra,
  • Stefan Kickinger,
  • Katharina Krepler,
  • Siamak Ansari-Shahrezaei

摘要

Objective

To investigate the long-term impact of half-fluence photodynamic therapy (PDT) on chorioretinal architecture in chronic central serous chorioretinopathy (cCSCR) through novel choroidal vascularity index (CVI) versus previously established subfoveal choroidal thickness (SFCT).

Methods

This post-hoc analysis included prospectively collected swept-source optical coherence tomography (SS-OCT) images of a total of 29 cCSCR and fellow eyes (FE), acquired before, one and 12 months after PDT. CVI, total choroidal area (TCA), luminal area (LA) and stromal area (SA) were calculated using validated binarization technique. Central macular thickness (CMT), SFCT and subretinal fluid (SRF) were assessed. Longitudinal changes following PDT and associations between all parameters were investigated.

Results

CVI, TCA, LA, SFCT and CMT significantly decreased at month 1 (all p < 0.001). From month 1 to 12, CVI (p < 0.001) and LA (p = 0.01) increased but remained significantly lower than at baseline (p = 0.001 and p < 0.001). SFCT and CMT remained stable (all p = 1.0). SA and all FE parameters showed no significant changes at any time point. Comparing affected and FE, there were significant CVI differences at baseline (p < 0.001), month 1 (p = 0.01) and 12 (p < 0.001). SRF was significantly associated with higher CVI (p < 0.001), LA (p = 0.031), SFCT (p = 0.038).

Conclusion

Half-fluence PDT significantly affects choroidal architecture, with sustained CVI and SFCT reductions 12 months post-treatment. Use of CVI as both a treatment response and disease activity marker is merited. There is a large discrepancy between CVI and SFCT, suggesting they each represent different anatomic responses. CVI proves to be a more specific and reliable CSCR biomarker than previously established SFCT.